Get the Stockscreener App
3.08
2.53%
-0.08
After Hours:
3.11
0.03
+0.97%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $3.08, with a volume of 4.34M.
It is down -2.53% in the last 24 hours and up +13.65% over the past month.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$3.16
Open:
$3.25
24h Volume:
4.34M
Relative Volume:
1.06
Market Cap:
$598.98M
Revenue:
$36,000
Net Income/Loss:
$-91.08M
P/E Ratio:
-3.285
EPS:
-0.9376
Net Cash Flow:
$-71.67M
1W Performance:
+4.76%
1M Performance:
+13.65%
6M Performance:
-22.22%
1Y Performance:
-35.29%
1-Day Range:
$3.08
$3.30
1-Week Range:
$2.914
$3.40
52-Week Range:
$2.56
$6.4399
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.08 | 591.20M | 36,000 | -91.08M | -71.67M | -0.9376 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Upgrade | Goldman | Sell → Neutral |
| Mar-18-26 | Initiated | Truist | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Here's why you should add Altimmune stock to your portfolio now - MSN
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) added to Russell 2000 Value Benchmark - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) added to Russell Microcap Value Benchmark Index - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
ALT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits
Price to book forward of Altimmune, Inc. – SWB:3G0 - TradingView
Enterprise value to revenue forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
Enterprise value to revenue forward of Altimmune, Inc. – SWB:3G0 - TradingView
Price to sales forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
Price to sales forward of Altimmune, Inc. – SWB:3G0 - TradingView
Price to earnings forward of Altimmune, Inc. – SWB:3G0 - TradingView
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
Price to earnings forward of Altimmune, Inc. – BMV:ALT1 - TradingView
Price to sales forward of Altimmune, Inc. – BMV:ALT1 - TradingView
Altimmune, Inc. Actuals & Estimates (NASDAQ:ALT) - TradingView
Enterprise value to EBIT forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
Altimmune Inc (ALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enterprise value to EBIT forward of Altimmune, Inc. – BMV:ALT1 - TradingView
Enterprise value to EBITDA forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
ALT stock guide to pemvidutide's MASH, AUD and ALD setup - MSN
ALT Forecast — Price Target — Prediction for 2027 - TradingView
A2N5Z6 Forecast — Price Target — Prediction for 2027 - TradingView
Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20? - Insider Monkey
Is Altimmune worth buying ahead of 2026 catalysts? - MSN
Altimmune Inc (ALT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Altimmune Inc (ALT) Valuation: PE, PB & Fair Value Analysis - TradingKey
ALT Initiated Coverage by Leerink PartnersRating Set to Outpe - GuruFocus
Leerink Partners Initiates Altimmune(ALT.US) With Buy Rating, Announces Target Price $10 - Moomoo
Leerink initiates Altimmune stock coverage citing liver drug data By Investing.com - Investing.com South Africa
Leerink initiates Altimmune stock coverage citing liver drug data - Investing.com
Leerink Partners Initiates Altimmune at Outperform With $10 Price Target - marketscreener.com
Altimmune Inc (ALT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ALT News | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune Inc (ALT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why is Altimmune (ALT) down 11.3% since last earnings report? - MSN
Altimmune Inc (ALT) Institutional Confidence - TradingKey
Altimmune Relocates Corporate Headquarters to Morristown, New Jersey - The Globe and Mail
Altimmune (ALT) Announces Move to New Jersey Headquarters to Boo - GuruFocus
Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide’s Broader Metabolic Data - Insider Monkey
Altimmune moving headquarters from Gaithersburg to New Jersey - The Business Journals
Altimmune Relocating Headquarters from Maryland to New Jersey - citybiz
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Apr 01 '26 |
Buy |
3.15 |
10,000 |
31,499 |
38,078 |
| Durso Jerome Benedict | President and CEO |
Apr 01 '26 |
Buy |
3.14 |
15,000 |
47,100 |
47,500 |
| WEAVER GREGORY L | Chief Financial Officer |
Mar 06 '26 |
Buy |
3.54 |
5,000 |
17,700 |
28,078 |
| Durso Jerome Benedict | President and CEO |
Mar 06 '26 |
Buy |
3.54 |
20,000 |
70,790 |
32,500 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '26 |
Option Exercise |
0.00 |
7,775 |
0 |
115,153 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '26 |
Option Exercise |
0.00 |
9,275 |
0 |
104,670 |
| Garg Vipin K | Director |
Jan 30 '26 |
Option Exercise |
0.00 |
26,775 |
0 |
429,225 |
| Jordt Raymond M | Chief Business Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
69,765 |
| Garg Vipin K | Director |
Jan 27 '26 |
Option Exercise |
0.00 |
41,200 |
0 |
420,348 |
| Roberts M Scot | Chief Scientific Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
100,143 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):